![]() If you opt-out your email will still be collected for registration purposes. ![]() The lynx is known as particularly sharp-eyed. Yet more scientific and technological breakthroughs are on the horizon. You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. Lynkeus derives from the Greek from lynx. Biotech is entering its next S-curve of growth as companies work to transform an array of innovationsgene therapies, stem-cell treatments, antisense DNA, siRNA, 1 CAR-T 2 into powerful new therapeutic tools. The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address. We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities. How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform. Further instrAction develops purification processes based on these proprietary phases. Both Miltenyi Biomedicine and Miltenyi Biotec were founded and are privately owned by Stefan Miltenyi who is advancing cellular therapy since 1989. The instrAction GmbH is a young, dynamic, and growing company which develops and produces modern chromatographic phases based on an innovative, patent protected technology (instrAction technology). Pharmaceutical and veterinary preparations, in particular for treating ocular conditions, metabolic disorders and tumours preparations for health care dietetic substances adapted for medical use.By accessing or using the AdisInsight platform you agree to the terms of use. Building on Miltenyi’s decades of experience, we are uniquely positioned to realize the great potential of the new cell and gene therapies and make them available to patients worldwide. ![]() Scientific and industrial research chemistry, biochemistry and biology services, in particular contract research and diagnostics chemistry and biochemistry services drawing up gene therapy protocols computer programming. ![]() Trademark is used in the following business:Ĭhemicals, in particular biochemical and molecular biological products used in industry and science.Ĭonsultancy, arranging and conducting of seminars, lectures and information events in the fields of molecular biology, genetic engineering, molecular diagnostics, gene therapy and molecular medicine. The current status of the LYNKEUS Bio Tech filing isīased on LYNKEUS BioTech GmbH, the LYNKEUS Bio Tech Lynkeus è una società di consulenza strategica focalizzata sulla progettazione e implementazione di soluzioni IT avanzate nelle scienze biomediche e oltre. The company is focusing its research and development on diseases of the eye. Patentanwälte Isenbruck Bösl Hörschler PartG mbB About Lynkeus BioTech Developer of pharmaceuticals for ophthalmology, especially age-related macular degeneration (AMD), vascular eye disorders, and chronic inflammation (e.g. PATENTANWÄLTE ISENBRUCK BÖSL HÖRSCHLER PARTG MBB, In the course of its multiple activities, Lynkeus has been interacting with over 100 partners and customers, ranging from: academia (Coventry University, Delft University of Technology, Erasmus Universitair Medisch Centrum Rotterdam, HES-SO, Johns Hopkins University, Katholieke Universiteit Leuven, London School of Economics, McGill University. Please accept Functional Cookies in your cookie settings. The legal correspondent for LYNKEUS Bio Tech trademark is Wacker Biotech GmbH Production Site To show you additional content, we need your permission to set cookies. The LYNKEUS Bio Tech mark is filed in the category ofĬomputer & Software Services & Scientific Services LYN 001 is a novel peptide that is undergoing clinical development with the German-based biotechnology company, Lynkeus BioTech GmbH, for the potential LYN 001 - AdisInsight Either you have JavaScript disabled or your browser does not support Javascript. Trademark Application Number is a unique ID to identify the LYNKEUS Bio Tech mark in EUIPO. The LYNKEUS Bio Tech trademark was assigned an Application Number # 002702918 – by the European Union Intellectual Property Office (EUIPO). LYNKEUS Bio Tech European Union Trademark Information By LYNKEUS BioTech GmbH
0 Comments
Leave a Reply. |